Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
CardioKine Inc. Cardiokine Biopharma, LLC Biogen Idec |
---|---|
Information provided by: | CardioKine Inc. |
ClinicalTrials.gov Identifier: | NCT00660959 |
The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIDH.
Condition | Intervention | Phase |
---|---|---|
Hyponatremia |
Drug: lixivaptan Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia |
Estimated Enrollment: | 100 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | July 2010 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Active Comparator: Experimental
lixivaptan
|
Drug: lixivaptan
oral capsule
|
Placebo: Placebo Comparator
placebo
|
Drug: placebo
oral capsule
|
Phase I Phase II clinical trials have demonstrated that lixivaptan may play an important role in treating hyponatremia and the signs and symptoms of water retention associated with HF, liver cirrhosis with ascites (LCWA) and syndrome of inappropriate antidiuretic hormone (SIADH). Lixivaptan was previously evaluated in disease states characterized by hyponatremia with euvolemia (SIADH)and hyponatremia combined with fluid overload (HF, LCWA). Lixivaptan resulted in correction in hyponatremia together with a marked aquaresis in subject with volume overload. The present study is designed to confirm and extend the observation from previous studies that lixivaptan therapy corrects hyponatremia, in euvolemic subject, including subjects with SIDH.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
demeclocycline, lithium carbonate, urea, or conivaptan
Contact: Cardiokine Biopharma, LLC | 215-399-1200 |
Responsible Party: | Cardiokine, Inc ( Cardiokine, Inc ) |
Study ID Numbers: | CK-LX3405 |
Study First Received: | April 15, 2008 |
Last Updated: | August 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00660959 History of Changes |
Health Authority: | United States: Food and Drug Administration; United States: Institutionl Review Board |
Hyponatremia Serum Sodium Fluid Overload |
Heart Failure Acute Heart Failure Vasopressin Antagonist |
Arginine Vasopressin Heart Failure Metabolic Diseases Hyponatremia |
Vasopressins Water-Electrolyte Imbalance Metabolic Disorder |
Metabolic Diseases Hyponatremia Water-Electrolyte Imbalance |